Stock Price Quote

LAURUS LABS LTD.

NSE : LAURUSLABSBSE : 540222ISIN CODE : INE947Q01028Industry : Pharmaceuticals & DrugsHouse : Private
BSE1967.0031 (+1.6 %)
PREV CLOSE ( ) 1936.00
OPEN PRICE ( ) 1947.05
BID PRICE (QTY) 1966.50 (14)
OFFER PRICE (QTY) 1967.00 (83)
VOLUME 49414
TODAY'S LOW / HIGH ( )1917.10 1973.70
52 WK LOW / HIGH ( )822.85 1981
NSE1973.3028.3 (+1.46 %)
PREV CLOSE( ) 1945.00
OPEN PRICE ( ) 1943.00
BID PRICE (QTY) 1973.10 (215)
OFFER PRICE (QTY) 1973.30 (231)
VOLUME 1427983
TODAY'S LOW / HIGH( ) 1918.10 1973.90
52 WK LOW / HIGH ( )823.1 1955
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 19-09 2005
Management Info
Ravindranath Kancherla - Chairman - Managing Director
Registered Office

Address Laurus Enclave, Plot Office 01,Edulapaka Bonangi Village, Parawada,Mandal, Anakapalli,
Vishakhapatnam,
Andhra Pradesh-531021

Phone 0891 6821101 / 1102

Email info@lauruslabs.com

Website www.lauruslabs.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

31Aug Laurus Labs submits analyst meet intim
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Re..
08Jun Laurus Labs informs about AGM
Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosur..
08May Laurus Labs informs about newspaper a
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..
02May Laurus Labs informs about press release
Laurus Labs has informed that it enclosed copies of the newspaper advert..
20Feb Laurus Labs informs about disclosure
Laurus Labs has informed that it enclosed disclosure under Regulation 29..

Financials

in Millions
QTR Jun 26 ANNUAL 26
Net Profit2899.67404.80000000001
Gross Profit 3881.7 9940.90000000001
Operating Profit 5191.315156.9
Net Sales 17571.660890.7

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Concord Biotech (BSE)
peergroup  1520.90 (4.70%)
M.Cap ( in Cr)15253.04
Onesource Specialty (BSE)
peergroup  1603.00 (3.72%)
M.Cap ( in Cr)18382.06
Torrent Pharma (BSE)
peergroup  4970.00 (0.84%)
M.Cap ( in Cr)189423.19
SMS Pharmaceuticals (BSE)
peergroup  455.70 (8.72%)
M.Cap ( in Cr)4184.84
Dr. Reddy's Labs. (BSE)
peergroup  1173.35 (2.85%)
M.Cap ( in Cr)97661.72

Shareholding Pattern

NON-INSTITUTION 30.79%
PROMOTERS 27.47%
FI/BANKS/INSURANCE 2.33%
MUTUAL FUNDS/UTI 10.15%
GOVERNMENT 0%
FII 0%

About Laurus Labs Ltd.

Laurus Labs Ltd. was incorporated in the year 2005. Its today's share price is 1967. Its current market capitalisation stands at Rs 106225.38 Cr. In the latest quarter, company has reported Gross Sales of Rs. 60890.7 Cr and Total Income of Rs.61665 Cr. The company's management includes Shekhar Chintamani Mande, Sutapa Banerjee, Ramesh Subrahmanian, Karnam Sekar, Soumya Chava, Krishna Chaitanya Chava, CV Lakshmana Rao, V Ravi Kumar, Satyanarayana Chava, Ravindranath Kancherla, G Venkateswar Reddy.

It is listed on the BSE with a BSE Code of 540222 , NSE with an NSE Symbol of LAURUSLABS and ISIN of INE947Q01028. It's Registered office is at Laurus Enclave, Plot Office 01,Edulapaka Bonangi Village, Parawada,Mandal, AnakapalliVishakhapatnam-531021, Andhra Pradesh. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells LLP, SR Batliboi & Associates LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.